Cargando…
Neutrocytopenia associated with a lurasidon therapy in a patient with paranoid schizophrenia
INTRODUCTION: Lurasidon is a relatively new, second-generation antypsychotic drug with an interesting receptor profile. It is considered safe and has a low risk of side effects. This drug is effecitve in reducing the productive symptoms of schizophrenia, but also has a positive effect on negative sy...
Autores principales: | Mielczarek, Z., Trędzbor, B., Krysta, K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10478948/ http://dx.doi.org/10.1192/j.eurpsy.2023.2261 |
Ejemplares similares
-
Neutropenia in a schizophrenia patient following combined lurasidone and paliperidone therapy: a case report
por: Mielczarek, Zuzanna, et al.
Publicado: (2023) -
Electroconvulsive therapy in a patient with resistant paranoid schizophrenia treated with clozapine
por: Castelao-Almodóvar, S., et al.
Publicado: (2021) -
Treatment Compliance in the Long-Term Paranoid Schizophrenia Telemedicine Study
por: Krzystanek, Marek, et al.
Publicado: (2017) -
The correlation beteen lifestyle and risk of metabolic syndrome in schizophrenia
por: Krysta, K., et al.
Publicado: (2023) -
Lurasidone augmentation to clozapine in treatment resistant schizophrenia: A pilot study
por: Arienti, V., et al.
Publicado: (2023)